[Osteoclastogenesis inhibitory factor (OCIF)/OPG (a novel therapeutic candidate for the treatment of metabolic bone diseases)].
Tsuda
Eisuke
E
Research Institute of Life Science, Snow Brand Milk Products Co., Ltd.
D000818:Animals; D001851:Bone Diseases, Metabolic / Q000188:drug therapy*; D006023:Glycoproteins / Q000502:physiology / Q000627:therapeutic use; D006801:Humans; D010024:Osteoporosis / Q000188:drug therapy; D053244:Osteoprotegerin; D018160:Receptors, Cytoplasmic and Nuclear / Q000502:physiology / Q000627:therapeutic use; D018124:Receptors, Tumor Necrosis Factor
D006023:Glycoproteins; D053244:Osteoprotegerin; D018160:Receptors, Cytoplasmic and Nuclear; D018124:Receptors, Tumor Necrosis Factor; C506030:TNFRSF11B protein, human